evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,543 questions · 2,589 findings · 168 reviews · Schizophrenia

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 601 · 23.2%GRADE not reported 446 · 17.2%Very low 721 · 27.8%Low 505 · 19.5%Moderate 274 · 10.6%High 42 · 1.6%

Droperidol vs haloperidol

Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) · acute psychosis

Droperidol leads to lower global state: use of additional medication ‐ by 60 minutes after… compared with haloperidol (high certainty).

1 finding from 1 review

VALPROATE + ANTIPSYCHOTICS vs placebo/no adjunctive treatment + antipsychotics

Response to treatment (medium term) Clinically important response to treatment as defined by each study · patients with schizophrenia

VALPROATE + ANTIPSYCHOTICS may leads to higher clinically significant response: important change As defined by each… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).

1 finding from 1 review

VALPROATE + ANTIPSYCHOTICS vs placebo/no adjunctive treatment + antipsychotics

Acceptability of treatment ‐ leaving the study early · patients with schizophrenia

It is very uncertain whether VALPROATE + ANTIPSYCHOTICS changes leaving the study early: Acceptability of treatment Leaving the… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (very low certainty).

1 finding from 1 review

VALPROATE + ANTIPSYCHOTICS vs placebo/no adjunctive treatment + antipsychotics

Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia

VALPROATE + ANTIPSYCHOTICS showed no clear difference in leaving the study early: Overall tolerability Leaving the study… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Adverse events: Specific ‐ prolactin‐related ‐ long term It is unclear how adverse events were reported · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related ‐ long term It is… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Weight gain · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ weight increase ‐ long term It is unclear… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Adverse events: Nervous system disorders (inc. EPS) ‐ long term It is unclear how adverse events were reported · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Nervous system disorders (inc. EPS) ‐ long term It… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs RISPERIDONE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ short term compared with ORAL RISPERIDONE (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs RISPERIDONE

Adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐ short term · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐… compared with ORAL RISPERIDONE (moderate certainty).

1 finding from 1 review